Suppliers and packagers for generic pharmaceutical drug: loxapine

loxapine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549	NDA	Alexza Pharmaceuticals, Inc.	51097-001-02	5 INHALER in 1 CARTON (51097-001-02) / 1 AEROSOL, POWDER in 1 INHALER (51097-001-01)	2026-07-06

Suppliers and packagers for generic pharmaceutical drug: loxapine

Last updated: July 8, 2026

LOXAPINE Suppliers: API, Key Intermediates, Finished-Dose Sources, and Supply-Chain Risks

LOXAPINE is a legacy central nervous system drug used for schizophrenia (including oral and inhalation presentations in some markets). Supplier availability is typically split between (1) API manufacturers, (2) specialized inhalation and sterile-oriented manufacturers for products where applicable, and (3) packagers/finished-dose license holders. Specific supplier lists and named manufacturers cannot be produced from the information provided.

What suppliers make lo xapine API (active pharmaceutical ingredient) for generic and branded products?

There are three supply-chain layers relevant to lo xapine API procurement:

• API synthesis and isolation: chemical manufacturers producing lo xapine as the free base or salt form required by downstream processes.
• Salt-form and solid-state control: manufacturers that can deliver consistent polymorph/particle-size profiles for tablet or capsule manufacturing.
• Regulatory dossier readiness: suppliers that provide DMF/CEP support (or bridge packages) for FDA and other agency submissions.

Typical due-diligence deliverables buyers require from API suppliers

• DMF number (FDA) or equivalent dossier references (EMA/CEP where applicable)
• Batch certificates of analysis (CoA) with impurity panels
• Residual solvent statements and elemental impurity reports
• GMP status and quality agreement coverage (including change control)

Which companies supply finished lo xapine dosage forms (tablets/capsules) and who holds regulatory marketing authorization?

Finished-dose supply depends on the presentation used in the target market:

• Oral solid dose (tablets/capsules): usually sourced from a small set of manufacturers with validated tablet/capsule lines and stable impurity controls.
• Inhalation formulations: require additional specialized manufacturing and QA controls (device integration, aerosol performance, and sterility-adjacent controls depending on the manufacturing scheme).

What to check to identify the real “supplier” behind a marketing authorization

• Labeler/manufacturer listed on the package insert
• Site of manufacture (as shown on regulatory labels)
• Contract manufacturing records where the marketing authorization holder is distinct from the physical manufacturer

Do lo xapine inhalation products require different suppliers than oral products?

If the commercial market includes an inhalation lo xapine product, it creates separate sourcing requirements:

• Specialized formulation and aerosolization performance testing
• Device and container closure compatibility work
• Tight particle-size distribution controls and consistent delivery-unit dose

These requirements typically narrow the eligible supplier pool compared with oral solid dose.

How do buyers source lo xapine from distributors without compromising quality?

For mature generics and legacy APIs, distributors often market through channel partnerships. Procurement controls should focus on:

• Verification that the distributor sources from qualified GMP API plants
• Traceability to batch-level CoA and manufacturing site
• Chain-of-custody and temperature/humidity controls where relevant
• Anti-counterfeit documentation for API and finished dose

What raw-material and intermediate suppliers matter for lo xapine manufacturing?

Lo xapine API is synthesized through multi-step chemical routes. The practical bottleneck suppliers usually include:

• Key chemical intermediates that determine impurity profile
• Hydrogenation/oxidation reagents where residual impurities carry over
• Solvents used in isolation and crystallization steps

Procurement should prioritize suppliers with impurity clearance experience and robust change-control history.

What are the main supply risks for lo xapine (single-source API, quality holds, and lead times)?

Common supply-chain constraints for older CNS drugs include:

• Narrow base of qualified API plants
• Long lead times for requalification after site or process changes
• Regulatory quality issues that trigger batch holds or delayed launches

Buyers typically manage this with dual-sourcing, longer qualification timelines, and contractual quality agreement terms.

Which supplier standards should be required for lo xapine API release (GMP and testing)?

For high-reliability sourcing, buyers typically require:

• GMP compliance at the API plant level
• Validated impurity method or fit-for-purpose release testing
• Stability program data aligned to proposed retest/expiry
• Controlled drift limits for assay and known impurities

Key Takeaways

• “Suppliers for lo xapine” breaks into API manufacturers, finished-dose manufacturers/labelers, and (where applicable) specialized inhalation formulators.
• Named supplier lists cannot be stated from the provided prompt alone.
• The highest leverage procurement checks are DMF/dossier support, GMP site verification, impurity control capability, and batch traceability.

FAQs

1. How can I identify the actual lo xapine API manufacturer behind a distributor label?
2. What dossier pathway is most commonly used for lo xapine API submissions in the US?
3. Do lo xapine salt forms change supplier requirements and qualification testing?
4. What lead-time differences exist between qualifying a new lo xapine API supplier and a finished-dose manufacturer?
5. How do quality agreement terms typically address impurity drift and change notifications for lo xapine?

References (APA)

1. FDA. (n.d.). Drug Master Files (DMFs). U.S. Food and Drug Administration.
2. EMA. (n.d.). European Medicines Agency: Regulatory and GMP guidance. European Medicines Agency.